Takeda Pharmaceutical Co. Ltd. has logged a generally solid last quarter of results before the impact of its acquisition of Shire PLC begins to kick in, with mainstay products growing globally and the results of ongoing cost savings driving margin improvement.
While again committing to the general principle of non-core asset sales to pay down debt associated with the acquisition, formally...







